Device Trial Radar · NCT00100087
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Theragenics CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 23, 2004
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
Conditions
- Macular Degeneration
- Choroidal Neovascularization
Interventions
Ocular BrachytherapyDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of serious adverse events 30 to 270 days after treatment
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Theragenics Clinical Site
Atlanta, Georgia · Recruiting
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.